Journal of Traditional Chinese Medicine ›› 2024, Vol. 44 ›› Issue (3): 581-585.DOI: 10.19852/j.cnki.jtcm.20240402.005
• Original articles • Previous Articles Next Articles
Neiguan (PC6) acupoint stimulation for preventing chemotherapy-induced nausea and vomiting: a cost-effective supplement in guideline-inconsistent chemotherapy-induced nausea and vomiting prophylaxis subgroup
YU Wenxi, TANG Lina, LI Hongtao, WANG Yonggang, SHEN Zan(
)
- Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China
-
Received:2023-01-22Accepted:2023-05-25Online:2024-06-15Published:2024-04-02 -
Contact:Prof. SHEN Zan, Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.sshenzzan@vip.sina.com Telephone: +86-18930177014 -
Supported by:National and Natural Science Foundation of China: DGKZ Acts as a Potential Oncogene in Osteosarcoma Proliferation through Interaction with ERK1/2 and MYC Pathway(Grant Number 81972521)
Cite this article
YU Wenxi, TANG Lina, LI Hongtao, WANG Yonggang, SHEN Zan. Neiguan (PC6) acupoint stimulation for preventing chemotherapy-induced nausea and vomiting: a cost-effective supplement in guideline-inconsistent chemotherapy-induced nausea and vomiting prophylaxis subgroup[J]. Journal of Traditional Chinese Medicine, 2024, 44(3): 581-585.
share this article
Table 1 Patient characteristics [n (%)]
| Characteristic | Overall (n = 373) | HEC (n = 291) | MEC (n = 82) | |
|---|---|---|---|---|
| Gender | Male | 227 (60.8) | 182 (62.5) | 45 (54.8) |
| Female | 146 (39.2) | 109 (37.5) | 37 (45.2) | |
| Age (years) | Median | 48 | 43 | 59 |
| ECOG score | 0 | 242 (64.8) | 188 (64.6) | 54 (65.8) |
| 1 | 128 (34.3) | 102 (35) | 26 (31.7) | |
| 2 | 3 (0.9) | 1 (0.4) | 2 (2.5) | |
| Primary cancer (>5%) | Bone and soft tissue sarcoma | 175 (46.9) | 171 (58.7) | 4 (4.9) |
| Breast cancer | 25 (6.7) | 20 (6.9) | 5 (6.1) | |
| Lung cancer | 51 (13.7) | 51 (17.5) | ||
| Colorectal cancer | 47 (12.6) | 47 (57.3) | ||
| Gastric cancer | 19 (5.1) | 5 (1.7) | 14 (17.1) | |
| Others | 56 (15) | 44 (15.2) | 12 (14.6) | |
| Chemo-protocol | With target therapy/Immunotherapy | 81 (21.7) | 52 (17.9) | 29 (35.4) |
| Without target therapy/Immunotherapy | 292 (78.3) | 239 (82.1) | 53 (64.6) | |
| CINV prevention | Guideline consistent | 246 (65.9) | 166 (57.0) | 80 (97.5) |
| Guideline inconsistent | 127 (34.1) | 125 (43.0) | 2 (2.5) | |
| Neiguan (PC6) acustimulation | With PC6 acustimulation | 216 (57.9) | 172 (59.1) | 44 (53.6) |
| Without PC6 acustimulation | 157 (42.1) | 119 (40.9) | 38 (46.4) | |
Table 1 Patient characteristics [n (%)]
| Characteristic | Overall (n = 373) | HEC (n = 291) | MEC (n = 82) | |
|---|---|---|---|---|
| Gender | Male | 227 (60.8) | 182 (62.5) | 45 (54.8) |
| Female | 146 (39.2) | 109 (37.5) | 37 (45.2) | |
| Age (years) | Median | 48 | 43 | 59 |
| ECOG score | 0 | 242 (64.8) | 188 (64.6) | 54 (65.8) |
| 1 | 128 (34.3) | 102 (35) | 26 (31.7) | |
| 2 | 3 (0.9) | 1 (0.4) | 2 (2.5) | |
| Primary cancer (>5%) | Bone and soft tissue sarcoma | 175 (46.9) | 171 (58.7) | 4 (4.9) |
| Breast cancer | 25 (6.7) | 20 (6.9) | 5 (6.1) | |
| Lung cancer | 51 (13.7) | 51 (17.5) | ||
| Colorectal cancer | 47 (12.6) | 47 (57.3) | ||
| Gastric cancer | 19 (5.1) | 5 (1.7) | 14 (17.1) | |
| Others | 56 (15) | 44 (15.2) | 12 (14.6) | |
| Chemo-protocol | With target therapy/Immunotherapy | 81 (21.7) | 52 (17.9) | 29 (35.4) |
| Without target therapy/Immunotherapy | 292 (78.3) | 239 (82.1) | 53 (64.6) | |
| CINV prevention | Guideline consistent | 246 (65.9) | 166 (57.0) | 80 (97.5) |
| Guideline inconsistent | 127 (34.1) | 125 (43.0) | 2 (2.5) | |
| Neiguan (PC6) acustimulation | With PC6 acustimulation | 216 (57.9) | 172 (59.1) | 44 (53.6) |
| Without PC6 acustimulation | 157 (42.1) | 119 (40.9) | 38 (46.4) | |
Table 2 Characteristics between with/without Neiguan (PC6) acustimulation [n (%)]
| Characteristic | Overall (n = 373) | With acustimulation (n = 216) | Without acustimulation (n = 157) | |
|---|---|---|---|---|
| Gender | Male | 227 | 127 (55.9) | 100 (44.1) |
| Female | 146 | 89 (60.9) | 57 (39.1) | |
| Age (years) | Median | 48 | 44 | 58 |
| ECOG score | 0 | 242 | 130 (53.7) | 112 (46.3) |
| 1 | 128 | 86 (67.1) | 42 (32.9) | |
| 2 | 3 | 0 | 3 (100) | |
| Primary cancer (>5%) | Bone and soft tissue sarcoma | 175 | 139 (79.4) | 36 (20.6) |
| Breast cancer | 25 | 16 (64) | 9 (36) | |
| Lung cancer | 51 | 15 (29.4) | 36 (70.6) | |
| Colorectal cancer | 47 | 13 (27.6) | 34 (72.4) | |
| Gastric cancer | 19 | 7 (36.8) | 12 (63.2) | |
| Others | 56 | 26 (46.4) | 30 (53.6) | |
| Chemo-protocol | With target therapy/immunotherapy | 81 | 30 (37) | 51 (63) |
| Without target therapy/immunotherapy | 292 | 186 (63.6) | 106 (36.4) | |
Table 2 Characteristics between with/without Neiguan (PC6) acustimulation [n (%)]
| Characteristic | Overall (n = 373) | With acustimulation (n = 216) | Without acustimulation (n = 157) | |
|---|---|---|---|---|
| Gender | Male | 227 | 127 (55.9) | 100 (44.1) |
| Female | 146 | 89 (60.9) | 57 (39.1) | |
| Age (years) | Median | 48 | 44 | 58 |
| ECOG score | 0 | 242 | 130 (53.7) | 112 (46.3) |
| 1 | 128 | 86 (67.1) | 42 (32.9) | |
| 2 | 3 | 0 | 3 (100) | |
| Primary cancer (>5%) | Bone and soft tissue sarcoma | 175 | 139 (79.4) | 36 (20.6) |
| Breast cancer | 25 | 16 (64) | 9 (36) | |
| Lung cancer | 51 | 15 (29.4) | 36 (70.6) | |
| Colorectal cancer | 47 | 13 (27.6) | 34 (72.4) | |
| Gastric cancer | 19 | 7 (36.8) | 12 (63.2) | |
| Others | 56 | 26 (46.4) | 30 (53.6) | |
| Chemo-protocol | With target therapy/immunotherapy | 81 | 30 (37) | 51 (63) |
| Without target therapy/immunotherapy | 292 | 186 (63.6) | 106 (36.4) | |
Table 3 Chemotherapy protocols in GICP/HEC group (n)
| Chemo-regimens | With Neiguan (PC6) acustimulation (n = 69) | Without Neiguan (PC6) acustimulation (n = 56) |
|---|---|---|
| Anthracycline | 19 | 12 |
| Cisplatin/carboplatin-based | 14 | 17 |
| Anthracycline/cisplatin Ifosfamide(≥2 g/m2) | 11 10 | 10 6 |
| VAC or AC | 13 | 10 |
| DTIC | 2 | 1 |
Table 3 Chemotherapy protocols in GICP/HEC group (n)
| Chemo-regimens | With Neiguan (PC6) acustimulation (n = 69) | Without Neiguan (PC6) acustimulation (n = 56) |
|---|---|---|
| Anthracycline | 19 | 12 |
| Cisplatin/carboplatin-based | 14 | 17 |
| Anthracycline/cisplatin Ifosfamide(≥2 g/m2) | 11 10 | 10 6 |
| VAC or AC | 13 | 10 |
| DTIC | 2 | 1 |
| 1. |
Soefje SA. Strategies to improve CINV outcomes in managed care. Am J Manag Care 2018; 24: S398-404.
PMID |
| 2. |
Gu L, Li J. The assessment and management of chemotherapy-induced nausea and vomiting among cancer patients in a chemotherapy ward: a best practice implementation project. JBI Database System Rev Implement Rep 2016; 14: 235-46.
DOI PMID |
| 3. |
Hesketh PJ, Palmas M, Nicolas P. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic. Support Care Cancer 2018; 26: 1151-59.
DOI PMID |
| 4. |
McCullough SW. Chemotherapy-induced nausea and vomiting: roles of pharmacists and formulary decision makers. Am J Manag Care 2017; 23: S266-71.
PMID |
| 5. |
Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. MASCC/ESMO antiemetic guidelines: introduction to the 2023 guidelines update. Support Care Cancer 2023; 32: 57.
DOI PMID |
| 6. |
Kirkegaard S, Kloth DD, Lagman R, et al. NCCN guidelines insights: antiemesis, version 2. 2017. J Natl Compr Canc Netw 2017; 15: 883-93.
DOI URL |
| 7. | Clark-Snow R, Affronti ML, Rittenberg CN. Chemotherapy induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer 2018; 26: 557-64. |
| 8. |
Dielenseger P, Börjeson S, Vidall C, et al. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey. Support Care Cancer 2019; 27: 4099-106.
DOI PMID |
| 9. |
Aapro M, Scotté F, Escobar Y, et al. Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 2021; 26: e1073-82.
DOI URL |
| 10. |
Athavale A, Athavale T, Roberts DM. Antiemetic drugs: what to prescribe and when. Aust Prescr 2020; 43: 49-56.
DOI PMID |
| 11. |
Konno R. Cochrane review summary for cancer nursing: acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cancer Nurs 2010; 33: 479-80.
DOI PMID |
| 12. | Xu X. The clinical observation of preventing vomiting after chemotherapy by Chinese herbal plaster on Yongquan acupoint. Shi Yong Zhong Yi Yao Za Zhi 2002; 9: 29. |
| 13. |
Treish I, Shord S, Valgus J, et al. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy. Support Care Cancer 2003; 11: 516-21.
DOI PMID |
| 14. |
Guo WC, Wang F. Effect of nerve electrical stimulation for treating chemotherapy-induced nausea and vomiting in patients with advanced gastric cancer: a randomized controlled trial. Medicine (Baltimore) 2018; 97: e13620.
DOI URL |
| 15. |
Li WH, Li D. Effect of electrical stimulation for chemotherapy-induced nausea and vomiting in patients with liver cancer. Medicine (Baltimore) 2019; 98: e15255.
DOI URL |
| 16. |
Dundee JW, McMillan C. Positive evidence for Neiguan (PC6) acupuncture antiemesis. Postgrad Med J 1991; 67: 417-22.
PMID |
| 17. |
Shen Y, Liu L, Chiang JS, et al. Randomized, placebo-controlled trial of K1 acupoint acustimulation to prevent cisplatin-induced or oxaliplatin-induced nausea. Cancer 2015; 121: 84-92.
DOI PMID |
| 18. |
Roscoe JA, Matteson SE, Morrow GR, et al. Acustimulation wrist bands are not effective for the control of chemotherapy-induced nausea in women with breast cancer. J Pain Symptom Manage 2005; 29: 376-84.
DOI URL |
| 19. |
Garcia GT, Ribeiro RF, Faria Santos IB, et al. Electrical stimulation of PC 6 to control chemotherapy-induced nausea and vomiting in patients with cancer: a systematic review and Meta-analysis. Med Acupunct 2021; 33: 22-44.
DOI PMID |
| 20. |
Navari RM, Schwartzberg LS. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. Onco Targets Ther 2018; 11: 6459-78.
DOI URL |
| 21. |
Cada DJ, Leonard J, Baker DE. Netupitant/palonosetron. Hosp Pharm 2015; 50: 310-25.
DOI PMID |
| 22. |
Tran N Le, Michael T Adler, Holly Ouillette, et al. Observational case series evaluation of the granisetron transdermal patch system (Sancuso) for the management of nausea/vomiting of pregnancy. Am J Perinatol 2017; 34: 851-55.
DOI PMID |
| 23. |
Lindley CM, Hirsch JD, O'Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992; 1: 331-40
DOI PMID |
| 24. | Clark-Snow R, Affronti ML, Rittenberg CN. Chemotherapy induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer 2018; 26: 557-64. |
| 25. |
Aapro M, Caprariu Z, Chilingirov P, et al. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: results of the nausea/emesis registry in oncology (NERO). Eur J Cancer 2022; 166: 126-13.
DOI PMID |
| 26. |
Nunley C, Wakim J, Guinn C. The effects of stimulation of acupressure point Neiguan (PC6) on postoperative nausea and vomiting: a review of literature. J Perianesth Nurs 2008; 23: 247-61.
DOI URL |
| 27. |
Chernyak GV, Sessler DI. Perioperative acupuncture and related techniques. Anesthesiology 2005; 102: 1031-49.
DOI PMID |
| [1] | ZHU Wenting, GUO Changqing, DU Mei, MA Yunxuan, CUI Yongqi, CHEN Xilin, GUO Changqing. Acupotomy alleviates knee osteoarthritis in rabbit by regulating chondrocyte mitophagy via Pink1-Parkin pathway [J]. Journal of Traditional Chinese Medicine, 2024, 44(3): 468-477. |
| [2] | WANG Dingyue, YU Yana, WANG Yiyuan, ZHANG Zhen. Musculoskeletal ultrasound to evaluate the efficacy of acupuncture: a review [J]. Journal of Traditional Chinese Medicine, 2024, 44(3): 629-632. |
| [3] | WANG Shaosong, SUN Jingqing, FENG Qingyin, LI Bin, WANG Xin, YUAN Fan, CUI Yingxue. Effectivenss of electroacupuncture for skeletal muscle pain in Parkinson's disease: a Clinical randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2024, 44(2): 388-395. |
| [4] | ZHANG Xinchang, HUANG Zheng, HUANG Peiyan, YANG Mengning, ZHANG Zhihui, NI Guangxia. Mechanism of acupuncture in attenuating cerebral ischaemia-reperfusion injury based on nuclear receptor coactivator 4 mediated ferritinophagy [J]. Journal of Traditional Chinese Medicine, 2024, 44(2): 345-352. |
| [5] | CHANG Junli, ZHAO Fulai, SUN Xingyuan, MA Xiaoping, ZHAO Peng, ZHOU Chujie, SHI Binhao, GU Wenchao, WANG Yongjun, YANG Yanping. Polyphyllin I enhances tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of human osteosarcoma cell growth via downregulating the Wnt/β-catenin pathway [J]. Journal of Traditional Chinese Medicine, 2024, 44(2): 251-259. |
| [6] | QIN Xiaoyu, WANG Chunai, XUE Jianjun, ZHANG Jie, LU Xiaoting, DING Shengshuang, GE Long, WANG Minzhen. Efficacy of electroacupuncture on myocardial protection and postoperative rehabilitation in patients undergoing cardiac surgery with cardiopulmonary bypass: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 1-15. |
| [7] | SUN Qianhui, CHENG Kai, DAI Xingye, YANG Zhiwen, WU Xiaoling, XU Chang, QIU Xinghua, GAO Xiaofeng, LIU Daonan, YANG Qirui. Effect of electroacupuncture at Neiguan (PC6) at different time points on myocardial ischemia reperfusion arrhythmia in rats [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 113-121. |
| [8] | LIU Tingting, LIU Tongou, LIU Mingfu. Effectiveness and safety of acupuncture in treatment of pregnancy-related symptoms: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 16-26. |
| [9] | YANG Yi, YE Huijun, ZHENG Huiling, JIN Lihua. Clinical observation on 90 cases of primary dysmenorrhea treated by buccal acupuncture therapy: a randomized controlled study [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 172-181. |
| [10] | LI Menghan, WANG Yu, RAN Dawei, YANG Xinming, DENG Shizhe, SHI Lei, MENG Zhihong. Effects of anterior sciatic nerve acupuncture on lower limb paralysis after cerebral infarction: study protocol for a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 205-211. |
| [11] | DU Zhongheng, CONG Wenjie, TANG Kejing, ZHENG Qiqi, SONG Zhiwei, CHEN Yong, YANG Su, ZHANG Chunwu, YE Tianshen. Electroacupuncture stimulating Zusanli (ST36), Sanyinjiao (SP6) in mice with collagen-induced arthritis leads to adenosine A2A receptor-mediated alteration of p38α mitogen-activated protein kinase signaling and inhibition of osteoclastogenesis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1103-1109. |
| [12] | QIN Xihui, PANG Jianli, XIONG Guan, FENG Jie. Bo′s abdominal acupuncture improves disordered metabolism in obese type 2 diabetic rats through regulating fibroblast growth factor 21 and its related adipokines [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1200-1208. |
| [13] | XU Yani, ZHANG Yutong, HE Weile, DAI Linglin, TANG Ding, WANG Jialing, ZHANG Xufen, CHEN Qin, CHEN Lifang, WANG Zhanglian, ZHAN Mingjie. Efficiency and safety of acupuncture for women with premature ovarian insufficiency: study protocol for a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1268-1274. |
| [14] | LI Menghan, YAN Yan, DENG Shizhe, WANG Yu, FU Yu, SHI Lei, YANG Jin, ZHANG Chunhong. Contralateral needling at the foot of unaffected side combining with rehabilitation treatment for motor dysfunction of hand after ischemic stroke: study protocol for a randomized controlled pilot trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 1034-1039. |
| [15] | WANG Kun, ZHOU Jie, CUI Shuai, WU Xin, ZHU Guoqi, WU Shengbing, ZHOU Meiqi. Electroacupuncture ameliorates cardiac dysfunction in myocardial ischemia model rats: a potential role of the hypothalamic-pituitary-adrenal axis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 944-954. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
